The company aims to harness the therapeutic potential of the postpartum placenta to develop effective, accessible, and affordable therapies for cancer, immunologic, infectious, and degenerative diseases. Celularity's innovative approach to cell therapy includes genetically modified and unmodified NK cells, engineered T cells including CAR-T cells, and mesenchymal-like adherent stromal cells. Headquartered in Florham Park, N.J., Celularity is leading the next evolution of cellular medicine with unparalleled scale, quality, and economics.